Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all types of chronic hand eczema, lasting for at least 6 months since initial diagnosis~* rated as severe by the physician~* unresponsive to highly potent topical corticosteroids, such as clobetasol~Exclusion Criteria:~* patients whose disease is adequately controlled by standard non-medicated therapy, including potent topical steroids, skin moisturizers, and avoidance of allergens and irritants~* patients with known allergens and irritants, who have not made a reasonable effort to avoid the substances~* patients with psoriasis lesions~* active fungal, bacterial or viral infections of the hands~* female patients who are pregnant or breastfeeding~* female patients of childbearing potential who cannot use or will not commit to use two effective methods of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Alitretinoin (Type: EXPERIMENTAL): Patients will receive alitretinoin 30mg capsule for up to 24 weeks
- Placebo (Type: EXPERIMENTAL): Patients will receive placebo 30mg capsule for up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).